
# Clinical Trial on the Impact of VCO as Adjuvant Against COVID-19

### Fabian M. Dayrit, PhD

Ateneo de Manila University, Philippines
National Academy of Science & Technology Philippines

International Coconut Community & Non-Aligned Movement Centre for South-South Technical Cooperation Health and Economic Benefits of VCO During COVID-19 and Beyond Webinar: December 08, 2020




### ackground

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus that causes the COVID-19 disease.

The spike protein (S) enables the virus to attach to ACE2 receptors of the body's cells and release the viral RNA inside the host cell.

SARS-CoV-2 has a lipid membrane which is not subject to mutation. This virus can be effectively inactivated by lipid solvents.



**SARS-CoV-2** 


### **Antiviral Strategies**

Target proteins

Target DNA / RNA


Drugs & Vaccines

Target lipid membrane



SARS-CoV-2

### SARS-CoV-2, ACE2, COVID-19



#### COVID-19

- Respiratory (ARDS)
- Gastrointestinal sys






- Kidney
- CNS / Brain
- Liver
- Lungs
- Endothelial cells



**Cytokine Storm** 

(modified from: Zou et al., Front. Med. Feb 8,2020)

### **Strategies Against COVID-19**



### Anti-viral

Repurposed drugs

### **Immune system**


- Vaccines
- Monoclonals
- Convalescent plasma

### **Anti-inflammatory**


- Drugs
- Convalescent plasma

### **Strategies Against COVID-19**

Clinical Trials.gov (as of Nov 29, 2020)	Number of Registered Studies	Number of Studies With Posted Results
Total	359,094	46,177
Drug or Biological Intervention	154,571	33,285



### **How does Coconut Oil become antiviral?**



- Coconut oil becomes antiviral and antibacterial after ingestion and hydrolysis with lipase enzyme
- The antiviral and antibacterial compounds include lauric acid (C12) and monolaurin (ML), and capric acid (C10) and monocaprin providing wide spectrum activity.
- Coconut oil contains 45-53% lauri acid and 7-8% capric acid.


### **VCO Anti-viral Studies**

### Anti-viral

(from literature)

n vitro: destroys virus membrane

Animal: Effective vs. Avian flu



### **Immune system**

(from literature)

- In vitro: T cell ↑
- Clinical: HIV: CD4/CD8 ↑


### **Anti-inflammatory**

(from literature)


- *In vitro*: IL-8 ↓
- Animal: iNOS ↓

### Viral lifecycle


#### 0. Free virus



### Results from In Vitro Experiments vs. SARS-CoV-2



### **Results from Clinical Studies on Mild COVID-19 Cases**





Imelda Angeles-Agdeppa, Ph.D., Jacus S. Nacis, MBA-H, Mario V. Capanzana, Ph.D., Fabian Antonio M. Dayrit, Ph.D., Carl Vincent D. Cabanilla, Jaime Montoya. M.D.

The study was implemented in Santa Rosa Community Hospital (SRCH) and Santa Rosa Community Isolation Unit (SRCIU). It was a randomized double-blind controlled intervention trial involving 57 suspect or probable cases of COVID-19 randomly allocated into 2 groups. The Intervention Group (VCO) received the VCO mixed with standardized meals while the Control Group received the standardized meals only. The recipes for the meals were developed by the DOST- FNRI. The intervention lasted for 28 days.

Dosage of VCO	
DURATION	DOSAGE
Initial Dose (Day 1-3)	0.6mL VCO /kg BW daily during breakfast
Succeeding dose (Day 4- 28)	1.2 mL VCO /kg BW distributed daily during breakfast and lunch
Subjects with reported intolerance	computed VCO /kg BW distributed daily during breakfast, lunch, and dinner

Monitoring Activity		
INDICATORS	FREQUENCY OF MONITORING	
Occurrence of signs and symptoms (Coughing, colds, body aches, headache, loss of taste, fever)	Daily	
C-Reactive Protein (CRP)	Day 1, 14, and 28	



### Results from Clinical Studies on Mild COVID-19 Cases

### The Effects of Virgin Coconut Oil among Suspect and Probable : Cases of COVID-19

Imelda Angeles-Agdeppa, Ph.D., Jacus S. Nacis, MBA-H, Mario V. Capanzana, Ph.D., Fabian Antonio M. Dayrit, Ph.D.,
Carl Vincent D. Cabanilla, Jaime Montova. M.D.




Figure 1. Percentage of patients with diminishing symptoms per group per day


### Recovery in COVID-19 related symptoms was more rapid in the VCO group vs. Control group.

- 5 out of 29 patients in the VCO group manifeste improvement as early as day 2 of intervention compared to only 1 from the Control group.
- Participants in the VCO group showed no more symptoms at day 18, while symptoms persisted some patients in the Control group until day 23.



### **Results from Clinical Studies on Mild COVID-19 Cases**





e mean level of C-reactive protein (CRP) in the CO group dropped much more rapidly mpared to the Control group.

The CRP of the VCO group normalized rapidly by day 14 and continued to drop until day 28. In comparison, the CRP level in the Control group dropped more slowly and stayed at the borderline until day 28.

This means that the VCO group experienced improvement from infection or inflammation within 14 days after start of VCO intervention.




Figure 2. Mean CRP levels by time periods



### VCO Antiviral and Anti-COVID-19 Studies

#### Anti-viral

(from literature)


n vitro: destroys virus membrane

Animal: Effective vs. Avian flu

In vitro vs SARS-CoV-2

Virucidal at low virus concentration

Enhances cell survival



#### **Immune system**

(from literature)

- In vitro: T cell ↑
- Clinical: HIV: CD4/CD8 ↑

### **Anti-inflammatory**

(from literature)

- In vitro: IL-8 ↓
- Animal: iNOS ↓

Clinical trial on mild COVID-19 sub

- COVID-19 symptoms ↓
- CRP ↓



- In vitro Study on the Efficacy of Lauric Acid and Derivatives Against SARS-CoV-2 (ADMU)
- The Beneficial Effects of VCO among Suspect and Probable Cases of COVID-19 (FNRI-DOST)



 Analysis and supply of VCO used in clinical study

# Virgin Coconut Oil is a Multi-Functional Adjuvant


### djuvant (to assist, auxiliary)

General definition: A substance that enhances the effect of a particular medical treatment.

Adjuvant therapy: treatment used after primary treatments

Drug adjuvant: to increase the efficacy or potency of drugs when given at the same time

Immunological adjuvant: to improve the immune response of a vaccine (or the body = immunomodulator?)




# Surviving COVID-19 and Beyond: Viral pandemics have been increasing

From 1900 – 1950, there was only 1 viral pandemic.

From 1950 - 2000, there were 8 viral pandemics.

From 2000 – 2019, there nave been 7 viral pandemics.




(from: Emergence of zoonotic diseases and environmental changes, Gwenaël Vourc'h, May 5 2020)

# Surviving COVID-19 and Beyond: We need a response that is sustainable

- Operation Warp Speed (US): almost \$10 B
- OECD: US\$137B estimate for global vaccine development
- Drug development: \$1B per drug, 10 years (estimate)
- Vaccine: \$3 to \$60 per dose (estimate)
- Remdesivir: \$3,000 per course

# Surviving COVID-19 and Beyond: We need solutions that are effective, affordable and appropriate



(Italy, Harvard Bus. Rev.)

(Rio de Janeiro City, Guardian)

(Zimbabwe, AP News)

# Surviving COVID-19 and Beyond: We need vaccines that are effective, affordable and appropriate


Frontiers in Microbiology July 2020 | Volume 11 | Article 1800

### Geographic and Genomic Distribution of SARS-CoV-2 Mutations


Daniele Mercatelli and Federico M. Giorgi \*\*

"The emergence of new mutations may force the development of new antiviral therapies, as well as the adaptation of current ones to tackle the new molecular structures of the virus."

- Will current vaccines be effective against:
  - A mutated SARS-CoV-2 virus?
  - SARS-CoV-2 viruses from different parts of the world?



# Surviving COVID-19 and Beyond: We need vaccines that are effective, affordable and long-lasting



Time Course of SARS-CoV-2 Antibody Binding and Neutralization Responses after mRNA-1273 Vaccination: Day 1 to 119 (4 mos)

How long does vaccine protection last?

(ref: Widge et al., Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. NEJM, December 3, 2020)

## Surviving COVID-19 and Beyond: The coconut can improve our health

### European Scientist

Covid 19 and the elephant in the room

By Aseem Malhotra - 16.04.2020

Obesity and chronic metabolic disease are killing COVID -19 patients.

The UK and USA, where more than 60% of adults are overweight or obese, have high mortality rates.

South Korea, which has low prevalence of obesity, experienced low mortality rate.

### **Healthy products from the Coconut**



- Coconut meat: diet and many other preparations, DCN
- Coconut milk
- · Coconut oil
- Coconut water
- · Nata de coco
- Coco sugar

### Surviving COVID-19 and Beyond: GO COCONUTS!

- In summary:
  - VCO has antiviral, immunomodulatory and anti-inflammatory activities
  - VCO is an affordable, readily available and healthy functional food
- We should increase support for R&D for VCO
  - Is VCO effective in protecting persons with comorbidities
  - Can VCO improve the efficacy of vaccines
- We should increase support for the coconut industry and the coconut farmer



# Surviving COVID-19 and Beyond: COCONUT SOLIDARITY TRIAL

